Table 2.

Disease-specific survival and HRs based on PD-1+ cell infiltrates

PD-1 cell densityaMedian survival (days)
NMeanMedianRangePD-1PD-1+HRb (95% CI)Pc
High-grade serous1953.300–532,0955,7920.362 (0.2293–0.5706)0.0007
CD3 (>5)1614.2500–532,7045,7920.5436 (0.3337–0.8857)0.0144
CD3 (<5)34000–0
CD8 (>5)1514.5300–533,0765,7920.6628 (0.3918–1.121)0.1251
CD8 (<5)44000–0
CD25/FOXP3 (>5)826.122.1250–532,4055,7920.3009 (0.1005–0.5175)0.0005
CD25/FOXP3 (<5)1131.600–44.52,0542,2380.8909 (0.4864–1.644)0.7188
Low-grade serous11
Mucinous30
Endometrioid1251.300–53dd0.76 (0.2490–2.320)0.63
Clear cell1280.5200–23d2,5211.806 (0.5647–5.773)0.32

NOTE: P values that are statistically significant (<0.05) are shown in bold.

  • aNumber of PD-1+ cells per 0.6-mm core (average of 2 cores), regardless of location within tumor.

  • bHR calculated using the log-rank test.

  • cP value using the log-rank (Mantel–Cox) test.

  • d Not reached.